Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/08/2026 07:10 PDT] NVAX Expected to Trade Up After Bullish Patterns Develop
• [04/30/2026 07:17 PDT] NVAX Expected to Trade Down After Bearish Patterns Develop
• [04/14/2026 09:17 PDT] NVAX Expected to Trade Down Short Term
• [04/09/2026 06:59 PDT] NVAX Expected to Trade Up After Bullish Patterns Develop
• [04/08/2026 07:16 PDT] NVAX Expected to Trade Up After Bullish Patterns Develop